Good User Reputation for Amoxicillin Oral Suspension - Artemether+ lumefantrine tabs – KeMing Medicines Detail:
FOB Price | Inquiry |
Min.Order Quantity | 1,000,000 tablets |
Supply Ability | 120,000,000 tablets/Month |
Port | Shanghai |
Payment Terms | T/T in advance |
Product Detail | |
Product name | Artemether+ lumefantrine tabs |
Specification | 20+120mg |
Description | A yellow Tablet |
Standard | Factory Standard |
Package | 24’s/blister |
Transportation | Ocean,Land,Air |
Certificate | GMP |
Price | Inquiry |
Quality guaranteeperiod | for 36 months |
Product Description | [Indication] This drug is an antimalarial: it inhibits the reproduction of the parasite responsible for malaria. It combines two substances that have a complementary mode of action and duration of action. It is used in the curative treatment of malaria. schema: a first dose at the time of diagnosis, then taken at least 8 hours, 24.36, 48 hours and 60 hours after the first dose. |
Product detail pictures:
Related Product Guide:
Medication & Dietary Supplement Interactions – What You Should Know about Drugs and Vitamins
Drugs, Vitamins, Pills, Pills, Pills
We pursue the administration tenet of "Quality is remarkable, Services is supreme, Status is first", and will sincerely create and share success with all customers for Good User Reputation for Amoxicillin Oral Suspension - Artemether+ lumefantrine tabs – KeMing Medicines, The product will supply to all over the world, such as: Croatia, Argentina, Latvia, To win customers' confidence, Best Source has set up a strong sales and after-sales team to deliver the best product and service. Best Source abides by the idea of "Grow with customer" and philosophy of "Customer-oriented" to achieve cooperation of mutual trust and benefit. Best Source will always stand ready to cooperate with you. Let's grow together!
By Candy from Berlin - 2018.12.28 15:18
The goods we received and the sample sales staff display to us have the same quality, it is really a creditable manufacturer.
By Antonio from Palestine - 2017.08.16 13:39